STOCKHOLM, May 10, 2010 (BUSINESS WIRE) -- Regulatory News: The New Drug Submission (NDS) for Onsolis (fentanyl buccal soluble film) has been approved by the Canadian regulatory authority, Health Canada. Onsolis is a new and patented product indicated for the management of breakthrough pain in cancer patients who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
Onsolis will be the first available fentanyl product with rapid onset of action approved in Canada and is expected to be available for patients during the third quarter 2010. The product will be commercialized by the joint venture between Meda (STO:MEDAA) and Valeant (Meda Valeant Pharma Canada Inc.).
About Onsolis Onsolis uses a unique delivery system designed to give rapid and reliable delivery of fentanyl. The product consists of a small dissolvable disc for application of fentanyl to the buccal (inner lining of cheek) membranes.
MEDA AB (publ) is a leading international specialty pharma company. Meda's products are sold in 120 countries worldwide and the company is represented by its own organizations in 50 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.
This information was brought to you by Cision http://www.cisionwire.com SOURCE: Meda CONTACT: MEDA AB Anders Larnholt, Vice President Corporate Development & IR Tel: +46 709-458 878 Copyright Business Wire 2010 -0- KEYWORD: Canada
Sweden
Europe
North America INDUSTRY KEYWORD: Health
Oncology
Pharmaceutical
Other Health
Research
Science SUBJECT CODE: Product/Service